Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 3,111 Shares

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 3,111 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $6.04, for a total value of $18,790.44. Following the completion of the sale, the insider directly owned 757,500 shares in the company, valued at $4,575,300. This represents a 0.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The shares were sold at an average price of $6.29, for a total value of $24,770.02.
• On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The stock was sold at an average price of $5.87, for a total value of $34,451.03.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total transaction of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The shares were sold at an average price of $5.81, for a total transaction of $76,081.95.
• On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The shares were sold at an average price of $6.03, for a total transaction of $24,952.14.
• On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total transaction of $48,171.20.
• On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $42,830.37.
• On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The stock was sold at an average price of $6.32, for a total transaction of $21,172.00.
• On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $9,342.30.
• On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The shares were sold at an average price of $6.54, for a total value of $28,560.18.

Clene Stock Performance

Shares of NASDAQ:CLNN opened at $6.28 on Thursday. The company has a market capitalization of $64.87 million, a PE ratio of -1.85 and a beta of 0.87. The stock has a fifty day moving average of $7.88 and a 200-day moving average of $6.39. Clene Inc. has a one year low of $2.28 and a one year high of $13.50.

Clene (NASDAQ:CLNN) last announced its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. As a group, research analysts forecast that Clene Inc. will post -5.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Lunt Capital Management Inc. lifted its position in Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after buying an additional 21,217 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Clene during the 2nd quarter valued at $47,000. Scoggin Management LP grew its holdings in shares of Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after acquiring an additional 42,750 shares in the last quarter. Finally, Jones Financial Companies Lllp acquired a new position in shares of Clene in the third quarter worth $29,000. 23.28% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CLNN. D. Boral Capital reiterated a “buy” rating and issued a $23.00 target price on shares of Clene in a report on Wednesday, December 10th. Benchmark restated a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a research report on Tuesday, October 14th. Finally, UBS Group reissued a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Clene has an average rating of “Moderate Buy” and an average target price of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).